Telos Capital Management’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-1,354
Closed -$208K 195
2023
Q1
$208K Sell
1,354
-235
-15% -$38.8K 0.03% 188
2022
Q4
$285K Buy
+1,589
New +$260K 0.04% 163
2022
Q1
Sell
-1,001
Closed -$254K 196
2021
Q4
$254K Sell
1,001
-195
-16% -$57K 0.03% 169
2021
Q3
$460K Buy
1,196
+177
+17% +$65.3K 0.06% 134
2021
Q2
$239K Buy
+1,019
New +$182K 0.03% 169

Other funds holding MRNA

Telos Capital Management's MRNA Position: Q2 2023 in Review

Telos Capital Management sold out of Moderna (MRNA) in Q2 2023, closing a stake of 1,354 shares — an estimated $208K sold.

Telos Capital Management first reported a position in MRNA in Q2 2021 and held it in 5 quarters. The position peaked at $460K in Q3 2021. 965 funds tracked by Wall St. Rank hold MRNA as of Q2 2023.

  • Telos Capital Management reported no remaining Moderna position as of Q2 2023 after selling out during the quarter.
  • Telos Capital Management sold 1,354 Moderna shares in Q2 2023, an estimated $208K.
  • Telos Capital Management first reported a position in Moderna in Q2 2021 and held it in 5 quarters.
  • Telos Capital Management's Moderna position peaked at $460K in Q3 2021.
  • 965 funds tracked by Wall St. Rank held Moderna as of Q2 2023.

Based on Telos Capital Management's 13F filing for Q2 2023, filed 21 Jul 2023.